Experienced life sciences patent attorney with considerable experience of coordinating patent strategies across the world including both patent prosecution and third party issues. Main areas of interest include antibodies, nucleic acid technologies and chemistry-biotechnology hybrid technologies.
BSc (Hons) Genetics, University of Wales, Swansea. Chartered Patent Attorney, European Patent Attorney, Member of FICPI and AUTM.
Jane read genetics at the University of Wales, Swansea, choosing to specialise in the areas of human disease genetics and gene therapy technologies. Jane was awarded the Genetics prize for the highest finals examination marks. Prior to realising that her career path lay in the patent profession, Jane spent two years studying medicine at Oxford University.
Jane joined Potter Clarkson in 2001 and became a partner in 2011. Jane has continued to work in the field of biotechnology and deals with subjects including recombinant technology, antibody therapies, drug screening assays and gene therapy technologies. She also handles patent applications in a number of biotechnology and chemistry cross-over areas, in particular combined chemical-biotechnology assays for biological sample assessment and the biological production of modified chemical compounds.
Jane provides commercially relevant advice tailored to the needs and commercial goals of each client, be they a University, SME or multinational corporation. Jane regularly advises her clients on all aspects of filing and prosecution strategy, as well as third party issues such as oppositions, third party observations and due diligence investigations. In particular, she has considerable experience planning worldwide patenting strategies and co-ordinating their implementation before numerous patent offices, as well as directly representing clients at the European Patent Office. Jane has been involved in a number of due diligence projects relating to company and IP acquisitions (for both acquirer and acquiree).
Jane is involved with an initiative to distribute funds to innovative business ideas arising out of East Midlands Universities, she has also been on the judging panel for the final of the Biotechnology YES competition for a number of years.
Jane has spoken at international conferences on various points of European law and practice and has authored a number of opinion and educational pieces on issues arising in UK and European law. Jane is also a founder member of the editorial panel of Life Sciences Intellectual Property Review magazine (LSIPR) and has been named as one of the 2017 WIPR Leaders.
Examples of clients:
- Promega Corporation
- BioInvent International AB
- LGC Group
- Imperial Innovations Limited
- Antikor Biopharma Limited
- Alkion Biopharma SAS
- Adelaide Research & Innovation (ARI)
- EP 1 535 069 (Drafting and worldwide prosecution for BioInvent International AB)
- EP 2 593 481 (Drafting and worldwide prosecution for BioInvent International AB)
- EP 1 594 962 (European prosecution for Promega Corporation)
- EP 1 935 986 (European prosecution for Promega Corporation)
- EP 1 416 970 (Drafting and worldwide prosecution for Antikor Biopharma Limited)
- EP 1 933 875 (Drafting and worldwide prosecution for Antikor Biopharma Limited)
- EP 1 359 906 (Worldwide prosecution for CXR Biosciences)
- US 8,487,003 (Worldwide prosecution for CXR Biosciences)
- LSIPR, May 2013 Newsletter - Self Collision of Patent Filings: an accident waiting to happen
- LSIPR, 2013 annual edition - Post Grant Challenges in Europe and the US